Nogapendekin alfa inbakicept (Anktiva)

Protein / enzyme therapeutic

Also known as ALT-803

Approvedregulatory verdict

Evidence outlook

Approved: Bladder Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USPancreatic Cancer · Phase 2 · investigational in the US

Also approved (2)
EU
  • Conditional authorisation: with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ
Product first approved 2026EMA
UK
  • ANKTIVA with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
Product first approved 20251stoncology.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Bladder Cancer
Non-Small Cell Lung Cancer
NCT07524257 · ImmunityBio, Inc.
2026-05-29 – 2029-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07492875 · ImmunityBio, Inc.
2026-04-15 – 2029-12-31 · Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia, Immunoparalysis
What this study did
Phase 2/3 (2)
Bladder Cancer
Non-Small Cell Lung Cancer
Phase 2 (36)
Bladder Cancer
NCT06829823 · ImmunityBio, Inc.
2025-11 – 2029-11 · Non-muscle Invasive Bladder Cancer (NMIBC)
What this study did
Non-Small Cell Lung Cancer
NCT05007769 · Washington University School of Medicine
2021-10-31 – 2026-04-30 · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT03563144 · ImmunityBio, Inc.
2018-08 – 2022-02-09 · Metastatic Pancreatic Cancer
What this study did
Other / comorbidity
NCT06765902 · ImmunityBio, Inc.
2025-12-15 – 2031-06-30 · High-risk Prostate Cancer
What this study did
NCT06765954 · ImmunityBio, Inc.
2025-12-01 – 2031-06-30 · High-risk Prostate Cancer
What this study did
NCT07628062 · ImmunityBio, Inc.
2026-07-22 – 2031-06-27 · HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT06061809 · ImmunityBio, Inc.
2024-08-07 – 2030-12-31 · Glioblastoma
What this study did
NCT07574541 · National Cancer Institute (NCI)
2026-11-24 – 2029-06-15 · Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
What this study did
NCT07085338 · St. Jude Children's Research Hospital
2025-11-10 – 2029-02-01 · Neuroblastoma Recurrent
What this study did
NCT07686380 · National Cancer Institute (NCI)
2026-10-01 – 2029-01-30 · Recurrent Prostate Cancer, Prostate Cancer
What this study did
NCT06161545 · National Cancer Institute (NCI)
2025-09-24 – 2028-12-01 · Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT07145164 · Michael Peluso, MD
2025-08-19 – 2028-12 · HIV
What this study did
NCT07477366 · ImmunityBio, Inc.
2026-04 – 2028-12 · Relapsed B-Cell Non-Hodgkin Lymphoma
What this study did
NCT07783789 · ImmunityBio, Inc.
2027-01-15 – 2028-08-13 · Sepsis
What this study did
NCT02782546 · Washington University School of Medicine
2017-01-30 – 2028-02-13 · Acute Myeloid Leukemia
What this study did
NCT05419011 · National Cancer Institute (NCI)
2023-05-08 – 2028-01-01 · Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
What this study did
NCT07578558 · ImmunityBio, Inc.
2026-07-06 – 2027-10-04 · Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness
What this study did
NCT07123727 · ImmunityBio, Inc.
2025-09-04 – 2027-03 · Long COVID, Long COVID Syndrome, Long Covid 19
What this study did
NCT07492888 · ImmunityBio, Inc.
2026-04-15 – 2027-01-15 · Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
What this study did
NCT07108036 · ImmunityBio, Inc.
2025-11-14 – 2026-10 · Long COVID
What this study did
NCT04847466 · National Cancer Institute (NCI)
2021-12-14 – 2026-01-06 · Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
What this study did
NCT04505501 · Thai Red Cross AIDS Research Centre
2021-03-01 – 2025-06-30 · HIV/AIDS
What this study did
NCT04491955 · National Cancer Institute (NCI)
2020-09-22 – 2024-08-16 · Small Bowel Cancers, Colorectal Cancers
What this study did
NCT05445882 · National Cancer Institute (NCI)
2024-04-01 – 2024-04-01 · Castration Resistant Prostate Cancer
What this study did
NCT03365661 · Masonic Cancer Center, University of Minnesota
2018-10-30 – 2023-01-01 · High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT03853317 · ImmunityBio, Inc.
2020-02-19 – 2022-09-19 · Merkel Cell Carcinoma
What this study did
NCT02989844 · Masonic Cancer Center, University of Minnesota
2017-04-12 – 2022-08-31 · Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
What this study did
NCT03054909 · Masonic Cancer Center, University of Minnesota
2017-09-19 – 2022-02-16 · FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
What this study did
NCT03554109 · ImmunityBio, Inc.
2018-09 – 2022-02-09 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT03003728 · University of Arkansas
2019-11-01 – 2020-07-08 · Multiple Myeloma
What this study did
NCT03050216 · Masonic Cancer Center, University of Minnesota
2017-05-16 – 2019-12-15 · Acute Myeloid Leukemia
What this study did
NCT02465957 · ImmunityBio, Inc.
2015-09-24 – 2018-03-19 · Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
What this study did
Phase 1/2 (32)
Bladder Cancer
NCT02138734 · ImmunityBio, Inc.
2014-07-21 – 2039-03-04 · Non-muscle Invasive Bladder Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05642195 · National Cancer Institute (NCI)
2026-11-24 – 2035-12-30 · Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
What this study did
NCT07355205 · Washington University School of Medicine
2026-07-07 – 2032-07-31 · Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT02523469 · Medical University of South Carolina
2016-01-08 – 2023-02-24 · Non-small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT03586869 · ImmunityBio, Inc.
2018-07-17 – 2019-08-01 · Pancreatic Cancer
What this study did
NCT03387098 · ImmunityBio, Inc.
2017-12-28 – 2019-01-15 · Pancreatic Cancer
What this study did
NCT03127098 · NantCell, Inc.
2017-06-26 – 2017-12-07 · Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
What this study did
Other / comorbidity
NCT06149481 · National Cancer Institute (NCI)
2024-03-26 – 2030-10-31 · Metastatic Colorectal Cancer
What this study did
NCT06253494 · National Cancer Institute (NCI)
2024-05-14 – 2028-12-31 · Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
What this study did
NCT03493945 · National Cancer Institute (NCI)
2018-05-01 – 2024-10-08 · Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
What this study did
NCT04247282 · National Cancer Institute (NCI)
2020-06-09 – 2023-06-12 · Head and Neck Cancer, Head and Neck Neoplasms
What this study did
NCT04927884 · ImmunityBio, Inc.
2021-09-08 – 2022-12-12 · Advanced Triple Negative Breast Cancer
What this study did
NCT01898793 · Washington University School of Medicine
2014-08-11 – 2022-04-04 · Leukemia, Myeloid, Acute
What this study did
NCT03167164 · ImmunityBio, Inc.
2017-12 – 2021-12-28 · Merkel Cell Carcinoma
What this study did
NCT03647423 · ImmunityBio, Inc.
2018-08-31 – 2021-12-28 · Chordoma, Unresectable Malignant Neoplasm
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT03169790 · ImmunityBio, Inc.
2017-12 – 2021-12-23 · Non Hodgkin Lymphoma
What this study did
NCT03387111 · ImmunityBio, Inc.
2018-01-09 – 2021-01-11 · Squamous Cell Carcinoma
What this study did
NCT04144335 · University of Minnesota
2020-01-01 – 2020-12-31 · Hiv, HIV/AIDS, HIV Infections, AIDS, AIDS and Infections, Aids/Hiv Problem
What this study did
NCT02384954 · Altor BioScience
2015-04-17 – 2020-12-13 · Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
What this study did
NCT01885897 · Masonic Cancer Center, University of Minnesota
2013-11-11 – 2020-07 · Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma, Myeloma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML)
What this study did
NCT03563170 · ImmunityBio, Inc.
2018-05-25 – 2019-08-23 · Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
What this study did
NCT03563157 · ImmunityBio, Inc.
2018-09-28 – 2019-08-21 · Colorectal Cancer Metastatic, mCRC
What this study did
Phase 1 (20)
Bladder Cancer
NCT07217496 · ImmunityBio, Inc.
2026-12 – 2032-01 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
What this study did
Pancreatic Cancer
NCT02559674 · Altor BioScience
2016-07 – 2018-02-21 · Advanced Pancreatic Cancer
What this study did
Other / comorbidity
NCT07261657 · Seth Pollack
2026-04-13 – 2032-09-02 · Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
What this study did
NCT07049432 · University of Utah
2026-02 – 2031-12 · B-cell Non Hodgkin Lymphoma
What this study did
NCT07756593 · Washington University School of Medicine
2026-11-30 – 2031-01-31 · Prostate Cancer, Metastatic Prostate Cancer
What this study did
NCT04898543 · ImmunityBio, Inc.
2021-06-21 – 2027-05-31 · Metastatic Solid Tumor
What this study did
NCT05618925 · ImmunityBio, Inc.
2025-08-22 – 2027-03-15 · Non Hodgkin's Lymphoma Refractory/Relapsed
What this study did
NCT04340596 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-05-21 – 2026-12-30 · HIV Infection
What this study did
NCT05245292 · Rockefeller University
2022-12-07 – 2025-12-31 · Human Immunodeficiency Virus
What this study did
NCT05769569 · Henry M. Jackson Foundation for the Advancement of Military Medicine
2023-09-01 – 2025-07-01 · HIV-1-infection
What this study did
NCT04290546 · Dana-Farber Cancer Institute
2020-07-20 – 2024-12-16 · Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT06040918 · ImmunityBio, Inc.
2023-10-04 – 2024-09-03 · Healthy Subjects
What this study did
NCT04808908 · University of Minnesota
2021-04-01 – 2023-01-01 · Hiv, HIV Infections, AIDS
What this study did
NCT03899480 · University of Minnesota
2019-05-01 – 2021-04-01 · Hiv, HIV Infections, Immune Deficiency
What this study did
NCT04385849 · ImmunityBio, Inc.
2020-07-22 – 2020-07-25 · COVID-19
What this study did
NCT02191098 · University of Minnesota
2015-06 – 2019-09-09 · HIV, Stable ART
What this study did
NCT02099539 · Altor BioScience
2014-10-06 – 2018-06-19 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT03381586 · Altor BioScience
2017-12-27 – 2018-03-13 · Healthy
What this study did
NCT01946789 · Altor BioScience
2014-05 – 2017-12 · Advanced Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nogapendekin Alfa Inbakicept (Anktiva): this drugApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nogapendekin alfa inbakicept (Anktiva) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2026-11 · NCT06829823 · CT.gov ↗
What to watch
December 2026 (2)
Phase 2Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck …Recruiting
Est. primary completion 2026-12-01 · NCT06161545 · CT.gov ↗
What to watch
Phase 1/2Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06253494 · CT.gov ↗
What to watch
2027 (7)
March 2027 (1)
Phase 2Long COVID, Long COVID Syndrome, Long Covid 19Recruiting
Est. primary completion 2027-03 · NCT07123727 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Platinum-resistant Ovarian CancerRecruiting
Est. primary completion 2027-05 · NCT06710288 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT05096663 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Colorectal Carcinoma, Colorectal Neoplasm, Lynch SyndromeActive not recruiting
Est. primary completion 2027-07-01 · NCT05419011 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-10-31 · NCT06149481 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2HIVEnrolling by invitation
Est. primary completion 2027-12 · NCT07145164 · CT.gov ↗
What to watch
Phase 2Relapsed B-Cell Non-Hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-12 · NCT07477366 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07217496 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Neuroblastoma RecurrentRecruiting
Est. primary completion 2028-02-01 · NCT07085338 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2SepsisNot yet recruiting
Est. primary completion 2028-05-12 · NCT07783789 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic TypeRecruiting
Est. primary completion 2028-06-15 · NCT07574541 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06745908 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2Recurrent Prostate Cancer, Prostate CancerRecruiting
Est. primary completion 2029-01-30 · NCT07686380 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Prostate Cancer, Metastatic Prostate CancerNot yet recruiting
Est. primary completion 2029-04-14 · NCT07756593 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2029-12-31 · NCT06061809 · CT.gov ↗
What to watch
2030 (2)
September 2030 (1)
Phase 1Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial SarcomaRecruiting
Est. primary completion 2030-09-02 · NCT07261657 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07628062 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-07-31 · NCT07355205 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

6 January 2027FDA action datePDUFA target date set for January 6, 2027
US, FDA · Source ↗

Recent

9 November 2026Topline resultQUILT-2.005 meets its primary endpoint in BCG-naive NMIBC
ImmunityBio · Source ↗
14 October 2026ApprovalFDA expands the Anktiva label to BCG-unresponsive non-muscle invasive bladder cancer
US, FDA · ImmunityBio · Source ↗
29 July 2026ApprovalUAE grants marketing authorization for Anktiva
AE, EDE · Source ↗
19 May 2026Filing acceptedFDA accepts sBLA for ANKTIVA plus BCG in papillary NMIBC
US, FDA · Source ↗